<DOC>
	<DOCNO>NCT02281396</DOCNO>
	<brief_summary>The purpose study evaluate safety Freeze-dried Rabies Vaccine （MRC-5 Cell ) healthy human age 10-60 year old , accord traditional Essen method ( 1-1-1-1-1 ) vaccination .</brief_summary>
	<brief_title>The Safety Research Freeze-dried Rabies Vaccine（MRC-5 Cell ) Chinese Humans</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1060 year old healthy people normal intelligence Obtain inform consent participant guardian , sign inform consent The participant guardian comply requirement clinical trial scheme The axillary temperature 37.0 ℃ less participant vaccinated rabies vaccine participant use antirabies passive immunization agent participant Suspect history injury hurt warmblooded mammal Female pregnant , lactation period , Pregnant plan clinical trial . participant allergy history , especially allergic neomycin , serious adverse reaction ever , Such allergy , hive , difficulty breathing , angioneurotic edema , abdominal pain . participant diagnose suspected immunodeficiency Autoimmune diseases , Immune system disorder . participant Thyroidectomy History , treat Thyroid disease past year . participant abnormal clot diagnosed doctor ( clot factor deficiency , coagulation disorder , platelet abnormality ) , coagulopathy . Participants history epilepsy , seizures convulsion , family history mental illness . Participants asplenia , functional asplenia , asplenia splenic resection circumstance . Participants immunosuppressive therapy , cytotoxic therapy , inhale corticosteroid past six month . ( It include Corticosteroid spray treatment Of allergic rhinitis , Surface treatment corticosteroid acute uncomplicated dermatitis ) Participants Received blood product past 3 month Participants Received investigational drug past one month . Participants receive Live attenuate vaccine 14 day clinical trial . Participants receive Subunit vaccine inactivate vaccine 7days clinical trial . Participants prevent treatment Antituberculosis . Participants fever 3 day receive Vaccine . ( Axillary temperature 38℃ ) Participants suffer severe chronic . ( Such Down 's syndrome , diabetes , sickle cell anemia neurological disorder , GuillainBarre syndrome ) ; Participants diagnose suspected suffering disease , Respiratory diseases , acute infection , Chronic active stage，Cardiovascular Disease , Severe hypertension , Skin disease , mother child HIVinfected , besides participant Treatment period malignant tumor , . According researcher , factor suitable Participants join clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>safety</keyword>
	<keyword>rabies vaccine</keyword>
	<keyword>MRC-5 cell</keyword>
</DOC>